A theme in which the contraction of the blood glucose self-monitoring device (BGM) market and the end of a US sales collaboration reduce sales volumes and revenue in the US, Germany, and elsewhere. It also includes periods of recovery driven by the fading impact of the collaboration’s termination and initiatives to raise unit prices and increase sales volumes, while the market contraction continues.